Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
Androgen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascula...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/8/2316 |
| _version_ | 1797606069908799488 |
|---|---|
| author | James Fradin Felix J. Kim Grace L. Lu-Yao Eugene Storozynsky William K. Kelly |
| author_facet | James Fradin Felix J. Kim Grace L. Lu-Yao Eugene Storozynsky William K. Kelly |
| author_sort | James Fradin |
| collection | DOAJ |
| description | Androgen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascular risk of men using androgen deprivation therapy. We also discuss racial disparities surrounding both prostate cancer and cardiovascular disease, emphasizing the importance of biological/molecular and socioeconomic factors in assessing baseline risk in patients beginning androgen ablation. Based on the literature, we provide recommendations for monitoring patients who are at high risk for a cardiovascular adverse event while being treated on androgen deprivation therapy. This review aims to present the current research on androgen deprivation therapy and cardiovascular toxicity with an emphasis on racial disparities and provides a framework for clinicians to decrease the cardiovascular morbidity in men that are being treated with hormone therapy. |
| first_indexed | 2024-03-11T05:10:09Z |
| format | Article |
| id | doaj.art-7a1053a9c100400abc0afec9a9ded08a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T05:10:09Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7a1053a9c100400abc0afec9a9ded08a2023-11-17T18:39:18ZengMDPI AGCancers2072-66942023-04-01158231610.3390/cancers15082316Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate CancerJames Fradin0Felix J. Kim1Grace L. Lu-Yao2Eugene Storozynsky3William K. Kelly4Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USADepartment of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USASidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USAJefferson Heart Institute, Department of Medicine, Sidney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USADepartment of Medical Oncology and Urology, Sidney Kimmel Cancer Center, Sidney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USAAndrogen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascular risk of men using androgen deprivation therapy. We also discuss racial disparities surrounding both prostate cancer and cardiovascular disease, emphasizing the importance of biological/molecular and socioeconomic factors in assessing baseline risk in patients beginning androgen ablation. Based on the literature, we provide recommendations for monitoring patients who are at high risk for a cardiovascular adverse event while being treated on androgen deprivation therapy. This review aims to present the current research on androgen deprivation therapy and cardiovascular toxicity with an emphasis on racial disparities and provides a framework for clinicians to decrease the cardiovascular morbidity in men that are being treated with hormone therapy.https://www.mdpi.com/2072-6694/15/8/2316androgen deprivation therapyprostate cancercardiovascular diseaseracial disparities |
| spellingShingle | James Fradin Felix J. Kim Grace L. Lu-Yao Eugene Storozynsky William K. Kelly Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer Cancers androgen deprivation therapy prostate cancer cardiovascular disease racial disparities |
| title | Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer |
| title_full | Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer |
| title_fullStr | Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer |
| title_full_unstemmed | Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer |
| title_short | Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer |
| title_sort | review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer |
| topic | androgen deprivation therapy prostate cancer cardiovascular disease racial disparities |
| url | https://www.mdpi.com/2072-6694/15/8/2316 |
| work_keys_str_mv | AT jamesfradin reviewofcardiovascularriskofandrogendeprivationtherapyandtheinfluenceofraceinmenwithprostatecancer AT felixjkim reviewofcardiovascularriskofandrogendeprivationtherapyandtheinfluenceofraceinmenwithprostatecancer AT gracelluyao reviewofcardiovascularriskofandrogendeprivationtherapyandtheinfluenceofraceinmenwithprostatecancer AT eugenestorozynsky reviewofcardiovascularriskofandrogendeprivationtherapyandtheinfluenceofraceinmenwithprostatecancer AT williamkkelly reviewofcardiovascularriskofandrogendeprivationtherapyandtheinfluenceofraceinmenwithprostatecancer |